Patient
Resources
When you advocate for yourself, you advocate for all of us.
GLP-1 Access in Your State
Your go-to guide for understanding GLP-1 access laws, compounding restrictions, and how to make your voice heard — no law degree required.
Across the United States, state and federal legislation is actively shaping access to compounded GLP-1 medications including semaglutide and tirzepatide. Bills targeting compounding pharmacies, bulk drug substance sourcing, prescription limits, and telehealth prescribing are moving through legislatures right now — and most patients have no idea. This resource tracks GLP-1 compounding legislation by state, explains what each bill means for your access in plain language, and gives you tools to contact your representatives. Updated regularly by GLP-1 Studio founder and patient advocate Amanda Bonello.
What a "20 Prescription Monthly Limit" Actually Means
One federal bill — H.R. 6509 — would limit compounding pharmacies to just 20 compounded GLP-1 prescriptions per month. That sounds manageable, right? Here's the reality: many specialty pharmacies fill 20 prescriptions per hour. A single pharmacy in Florida ships to patients across the country. Under this rule, they'd hit their monthly cap in the time it takes to brew a pot of coffee — and every patient waiting on their medication would be left without access.
GLP-1 Access by State
Click a highlighted state to see active legislation and what it means for your access.